# A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

> **NCT07354711** · PHASE1,PHASE2 · RECRUITING · sponsor: **3H Pharmaceuticals Co., Ltd.** · enrollment: 170 (estimated)

## Conditions studied

- Lung Cancer
- Stomach Cancer

## Interventions

- **DRUG:** 3H-10000

## Key facts

- **NCT ID:** NCT07354711
- **Lead sponsor:** 3H Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-04
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07354711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07354711, "A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07354711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*